Provider Involvement in Care During Initial Cancer Treatment and Patient Preferences for Provider Roles After Initial Treatment
Journal of Oncology Practice · 2019-04 · 15 (4) · e328-e337
DOI: 10.1200/jop.18.00497 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Oncology Practice, 2019-04. Verfasst von Archana Radhakrishnan und 8 weiteren Autor:innen. Beteiligte Einrichtung: 1 University of Michigan, Ann Arbor, MI. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, CCR NIH HHS, NCCDPHP CDC HHS.
Abstract (Originalsprache)
PURPOSE: Patients report strong preferences regarding which provider—oncologist or primary care provider (PCP)—handles their primary care after initial cancer treatment (eg, other cancer screenings, preventive care, comorbidity management). Little is known about associations between provider involvement during initial cancer treatment and patient preferences for provider roles after initial treatment. METHODS: Women who received a diagnosis of early-stage breast cancer in 2014 to 2015 were identified from the Georgia and Los Angeles County SEER registries and surveyed (N = 2,502; 68% response rate). Women reported the level of their providers’ involvement in their care during initial cancer treatment. Associations between level of medical oncologist’s participation and PCP’s engagement during initial cancer treatment and patient preferences for oncologist led ( v PCP led) other cancer screenings after initial treatment were examined using multivariable logistic regression models.
Results
During their initial cancer treatment, 20% of women reported medical oncologists participated substantially in delivering primary care and 66% reported PCPs were highly engaged in their cancer care. Two-thirds (66%) of women preferred medical oncologists to handle other cancer screenings after initial treatment. Women who reported substantial medical oncologist participation in primary care were more likely (adjusted odds ratio, 1.42; 95% CI, 1.05 to 1.91) and those who reported high PCP engagement in cancer care were less likely (adjusted odds ratio, 0.41; 95% CI, 0.31 to 0.53) to prefer oncologist-led other cancer screenings after initial treatment.
Conclusions
Providers’ involvement during initial cancer treatment may affect patient preferences regarding provision of follow-up primary care. Clarifying provider roles as early as during cancer treatment may help to better delineate their roles throughout survivorship.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- 1 University of Michigan, Ann Arbor, MI.
- 2 University of Southern California, Los Angeles, CA.
- 3 Emory University, Atlanta, GA.
- 4 Ann Arbor VA Center of Excellence in Health Services Research & Development, Ann Arbor, MI.
Förderung
- NCI NIH HHS
- CCR NIH HHS
- NCCDPHP CDC HHS
Zitieren
APA
Radhakrishnan, A., Li, Y., Furgal, A. K. C., Hamilton, A. S., Ward, K. C., Jagsi, R., Katz, S. J., Hawley, S. T., & Wallner, L. P. (2019). Provider Involvement in Care During Initial Cancer Treatment and Patient Preferences for Provider Roles After Initial Treatment. Journal of Oncology Practice, 15(4), e328-e337. https://doi.org/10.1200/jop.18.00497
Vancouver
Radhakrishnan A, Li Y, Furgal AKC, Hamilton AS, Ward KC, Jagsi R, et al. Provider Involvement in Care During Initial Cancer Treatment and Patient Preferences for Provider Roles After Initial Treatment. Journal of Oncology Practice. 2019;15(4):e328-e337. doi:10.1200/jop.18.00497
BibTeX
@article{Radhakrishnan2019,
author = {Radhakrishnan, Archana and Li, Yun and Furgal, Allison K C and Hamilton, Ann S and Ward, Kevin C and Jagsi, Reshma and Katz, Steven J and Hawley, Sarah T and Wallner, Lauren P},
title = {Provider Involvement in Care During Initial Cancer Treatment and Patient Preferences for Provider Roles After Initial Treatment},
journal = {Journal of Oncology Practice},
year = {2019},
volume = {15},
number = {4},
pages = {e328--e337},
doi = {10.1200/jop.18.00497}
}
EUVIMED